Self-Administered Drug Exclusion List (A53033) - R42 - Effective June 1, 2025

Date Posted: April 17, 2025

This billing and coding article has been revised and published for notice under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: June 1, 2025

Summary of Changes:

Added: CPT/HCPCS codes Q9999 Injection, Ustekinumab-aauz (Otulfi), biosimilar, 1 mg*; J3490, J3590, C9399 lebrikizumab-lbkz (Ebglyss); and J3490, J3590, C9399 ustekinumab-stba (SteQeyma)*

Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.

To view the complete listing of billing and coding articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Billing and Coding Articles webpage.

Last Updated Apr 17 , 2025